25 April 2017
I am writing to you because your participation and your vote in the upcoming Nicox Ordinary and Extraordinary General Meetings to be convened on May 16, 2017 are important.
With two pending New Drug Applications under review by the US Food and Drug Administration during the next six months, VyzultaTM, licensed to Bausch + Lomb, for patients with open angle glaucoma or ocular hypertension, and ZERVIATE (formerly AC-170) for the treatment of ocular itching associated with allergic conjunctivitis, we are on the last “mile” of our “marathon” to achieve the ultimate goal that each R&D company is dreaming of: to see their products brought to the marketplace where they can benefit patients.
We are confident that 2017 will finally be the transformational year that we have all been patiently long awaiting and we are fully committed to the long-term growth of our Company not only through the potential approvals and market entry of VyzultaTM and ZERVIATE, but also through the upcoming initiation of proof-of-concept Phase 2 clinical testing for our next-in-line pipeline candidates: NCX 4251 for the treatment of blepharitis, and NCX 470 for IOP lowering in patients with open angle glaucoma or ocular hypertension. With these two products candidates, which target high unmet need indications, we are well positioned to rapidly expand our footprint as a leading R&D player in ophthalmology.
We are working hard to ensure that Nicox’s potential is fully understood and recognized by the international markets, and we are confident that the pending decisions for both VyzultaTM and ZERVIATE, along with the advancement of our broad ophthalmic pipeline are all putting Nicox on the right path for sustained success. In order to achieve this, we need your support, specifically by voting in the upcoming Ordinary and Extraordinary General Meetings.
For this purpose, a proxy form, the draft resolutions, a guide explaining how to vote, and several other documents pertaining to the General Meetings are enclosed. You may either vote by proxy, by internet or attend the General Meetings in person on May 16, 2017 at 2:00 pm CET in the offices of Drakkar – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France. All the documents pertaining to the General Meetings are available on our website www.nicox.com (‘Shareholder Meetings’ button on the home page).
Should you have any question on the voting process, please contact our Investor Relations team either by e-mail at Age2017@nicox.com or by phone at +184.108.40.206.53.29.
With my best regards,